Interestingly, PPAR-γ antagonists may amelioratemetabolic disorders such as obesity, insulin resistance anddyslipidemia, by inhibition of adipocyte differentiation.PPAR-γ antagonists, tanshinone IIAand ß-cryptoxanthine,have been reported to reduce body weight, blood glucoseand serum TG in HFD-induced obese mice (37). Here, PPARG is linked to obesity due to melanocortin 4 receptor deficiency.